Cargando…

Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer

BACKGROUND: Prostate cancer (PC) represents a global health issue. Treatment for locally advanced and metastatic PC remains unsatisfactory. The androgen receptor (AR) has been validated in having a key role in both naïve and castrate-resistant PC (CRPC). However, the significance of other signalling...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armstrong, K, Ahmad, I, Kalna, G, Tan, S S, Edwards, J, Robson, C N, Leung, H Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241546/ https://www.ncbi.nlm.nih.gov/pubmed/21952621 http://dx.doi.org/10.1038/bjc.2011.367

Ejemplares similares

Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer
por: Mukherjee, R, et al.
Publicado: (2011)

NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression
por: McCall, P, et al.
Publicado: (2012)

Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer
por: Tam, L, et al.
Publicado: (2007)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer
por: Ahmad, I, et al.
Publicado: (2013)

The FGFR1 inhibitor PD173074 induces mesenchymal–epithelial transition through the transcription factor AP-1
por: Nguyen, P T, et al.
Publicado: (2013)

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
por: Punnoose, Elizabeth A, et al.
Publicado: (2015)

FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients
por: Streit, S, et al.
Publicado: (2006)

Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients
por: McCall, P, et al.
Publicado: (2008)

MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker
por: Goto, Yusuke, et al.
Publicado: (2015)

Inhibition of constitutive and cxc-chemokine-induced NF-κB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells
por: Seaton, A, et al.
Publicado: (2009)

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2014)

FGFR2 gene amplification and clinicopathological features in gastric cancer
por: Matsumoto, K, et al.
Publicado: (2012)

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer
por: Recine, Federica, et al.
Publicado: (2015)

Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments
por: Dudderidge, T J, et al.
Publicado: (2010)

Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer
por: Cihoric, N, et al.
Publicado: (2014)

Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease
por: Darby, S, et al.
Publicado: (2009)

Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline
por: Yates, C, et al.
Publicado: (2005)

Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer
por: Gowardhan, B, et al.
Publicado: (2005)

ERK5 signalling in prostate cancer promotes an invasive phenotype
por: Ramsay, A K, et al.
Publicado: (2011)

Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis
por: Matakidou, A, et al.
Publicado: (2007)

Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression
por: Chen, G, et al.
Publicado: (2010)

Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers
por: Xu, B, et al.
Publicado: (2013)

FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study
por: Su, X, et al.
Publicado: (2014)

Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer
por: Koike, H, et al.
Publicado: (2005)

Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients
por: Willder, J M, et al.
Publicado: (2013)

Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells
por: Hirata, H, et al.
Publicado: (2014)

Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues
por: Riddick, A C P, et al.
Publicado: (2005)

Is PTEN loss associated with clinical outcome measures in human prostate cancer?
por: McCall, P, et al.
Publicado: (2008)

Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy
por: Pham, Thy, et al.
Publicado: (2016)

Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1–PI3K–Rac1 pathway
por: Kamura, S, et al.
Publicado: (2010)

Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer
por: Dudderidge, T J, et al.
Publicado: (2007)

Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein
por: McClurg, Urszula L, et al.
Publicado: (2018)

Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies
por: St John, M A, et al.
Publicado: (2012)

Prognostic significance of CD44 variant 2 upregulation in colorectal cancer
por: Ozawa, M, et al.
Publicado: (2014)

Sox5 contributes to prostate cancer metastasis and is a master regulator of TGF-β-induced epithelial mesenchymal transition through controlling Twist1 expression
por: Hu, Jieping, et al.
Publicado: (2018)

The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone
por: Campbell, Esther J, et al.
Publicado: (2016)

The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder
por: Qayyum, T, et al.
Publicado: (2012)

Cytoglobin is upregulated by tumour hypoxia and silenced by promoter hypermethylation in head and neck cancer
por: Shaw, R J, et al.
Publicado: (2009)

Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
por: Jie, H-B, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ifpbjdghfaqjmepg1hm5k754kb